55
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

A Randomized Trial of Nelfinavir, Ritonavir, or Delavirdine in Combination with Saquinavir-SGC and Stavudine in Treatment-Experienced HIV-1-Infected Patients

, , , , , , , , , & show all
Pages 97-107 | Published online: 29 Jan 2015

REFERENCES

  • Report of the NIH panel to define principles of therapy of HIV infection. MMWR. 1998;47(RR-S):1–41.
  • Gulick RM, Mellors JW, Haylir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:733–739.
  • Delta Coordinating Committee. A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996;348:283–291.
  • Hammer SM, Katzenstein DA, Hughes MD, et al. A trial of monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimetre. N Engl J Med. 1996;335:1081–1089.
  • Schapiro JM, Winters MA, Stewart F, et al. The effect of high dose saquinavir on viral load and CD4+ T-cell count in HIV-infected patients. Ann Intern Med. 1996;124:1039–1050.
  • Perry CM, Noble S. Saquinavir soft-gel capsule formula-tion. Drugs. 1998;55:461–486.
  • Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther. 1998;63:452–464.
  • Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmaco-kinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS. 1997;11:F117–F120.
  • Cox SR, Batts DH, Stewart F, et al. Evaluation of the pharmacokinetic (PK) interaction between saquinavir and delavirdine in healthy volunteers. In: Fourth Conference on Retroviruses and Opportunistic Infections; 1997; Washing-ton, DC. Abstract 381.
  • Danner SA, Carr A, Leonard JM, et al. A short term study of safety, pharmacokinetic, and efficacy of ritonavir, an inhibi-tor of HIV-1 protease. N Engl J Med. 1995;333:1528–1533.
  • 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41: 1–19.
  • Wu EY, Wilkinson JM, Naret DG, et al. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B. 1997;695:373–380.
  • Gieschke R, Fotteler B, Steimer JL. Relationship between exposure to saquinavir monotherapy and antiviral re-sponse in HIV-positive patients. Clin Pharmacokinet. 1999;37:75–86.
  • Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA. 2000;18:2417–2426.
  • Race E, Gilbert SM, Sheldon JG, et al. Correlation of re-sponse to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. AIDS. 1998;12:1465–1474.
  • Mills G, Morgan J, Hales G, Smith D. Acute hypersensitivity with delavirdine. Antiviral Ther. 1999;4:51.
  • Hales G, Roth N, Smith D. Possible fatal interaction be-tween protease inhibitors and methamphetamine. Antiviral Ther. 2000;5:19.
  • Lawrence J, Schapiro J, Winters M, et al. Clinical resis-tance patterns and response to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced patients. J Infect Dis. 1999;179: 1356–1364.
  • Seminari E, Maggiolo F, Villani P, et al. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1 posi-tive patients heavily pretreated with nucleoside analogues and protease inhibitors. J Acquir Immune Defic Syndr. 1999;22:453–460.
  • Harrigan PR, Hertogs K, Verbiest W, et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community set-ting. AIDS. 1999;13:1863–1871.
  • Zolopa AR, Shafer RW, Warlord A, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med. 1999;131: 813–821.
  • Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998;12:1619–1624.
  • Tremblay C, Merrill DP, Chou TC, Hirsch MS. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 iso-lates. J Acquir Immune Defic Syndr. 1999;22:430–436.
  • Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected pa-tients treated with genotypic-guided therapy: Pharma-cological data from the Viradapt study. AIDS. 2000;14:1333–1339.
  • Rhone SA, Hogg RS, Yip B, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-in-fected adults: Results from a community-based study. AIDS. 1998;12:619–624.
  • Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: Implica-tions for therapeutic drug monitoring. AIDS. 1999;13:2083–2089.
  • Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure to protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11:F113—F116.
  • Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
  • Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–366.
  • Roth HP, Caron HS. Accuracy of doctors estimates and patients statements on adherence to a drug regimen. Clin Pharmacol Ther. 1978;23:361–370.
  • Mezzaroma I, Carlesimo M, Pinter E, et al. Clinical and immunologic response without decrease in viral load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis. 1999;29:1423–1430.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.